What do systematic reviews say?

Low molecular weight heparin vs no prophylaxis

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1978 participants
  GRADE not reported

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 1.85 [0.95, 3.59]
  5 studies · 1978 participants
  Moderate

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 0.98 [0.06, 15.72]
  1 study · 1451 participants
  Moderate

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 1.79 [0.84, 3.84]
  5 studies · 1978 participants
  Moderate

Lower blood pressure targets vs standard blood pressure targets

Lower blood pressure targets showed no clear difference in total mortality compared with standard blood pressure targets (moderate certainty).

• Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes only
  RR 1.05 [0.91, 1.23]
  7 studies · 9595 participants
  Moderate

Lower blood pressure targets vs standard blood pressure targets

Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).

• Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes only
  RR 1.01 [0.94, 1.08]
  7 studies · 9595 participants
  Low

Lower blood pressure targets vs standard blood pressure targets

Lower blood pressure targets showed no clear difference in total cardiovascular events compared with standard blood pressure targets (low certainty).

• Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes only
  RR 0.89 [0.8, 1]
  7 studies · 9595 participants
  Low

Lower blood pressure targets vs standard blood pressure targets

Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).

• Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.82, 1.29]
  6 studies · 9484 participants
  Moderate

Lower blood pressure targets vs standard blood pressure targets

It is very uncertain whether lower blood pressure targets changes participant withdrawals due to adverse effects compared with standard blood pressure targets (very low certainty).

• Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes only
  RR 8.16 [2.06, 32.28]
  3 studies · 801 participants
  Very low

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs unfractionated heparin

Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 0.66 [0.4, 1.1]
  5 studies · 418 participants
  Low

Low molecular weight heparin vs unfractionated heparin

Low molecular weight heparin showed no clear difference in recurrent VTE compared with unfractionated heparin (low certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 0.69 [0.27, 1.76]
  3 studies · 422 participants
  Low

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.6 [0.42, 0.88]
  8 studies · 5324 participants
  Moderate

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.48 [0.35, 0.67]
  9 studies · 5408 participants
  High

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.57 [0.46, 0.71]
  10 studies · 5743 participants
  High